Henry Ford Hospital

Contents

• Location

• Physicians

• NABTT Protocol Availability

• Contact Information

Location

Henry Ford Hospital
2799 W. Grand Blvd.
Detroit, MI 48202

NABTT Protocol Availability

• Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults with Newly Diagnosed Malignant Glioma

• Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma
• A Safety Run-In/Randomized Phase II Trial of EMD 121974 in Conjunction with Concomitant and Adjuvant Temozolomide with Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme
• A Phase II Trial of Talampanel in Conjunction with Radiation Therapy with Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme

Class C: (Recurrent High Grade Astrocytoma, with Measurable Disease)

• A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered with a Fixed Dose of BCNU Every 6 weeks in Patients with Recurrent Glioblastoma Multiforme

• Phase I Evaluation of the Safety of PS341 in the Treatment of Recurrent Gliomas

• A Phase I Trial of BAY 43-9006 for Patients with Recurrent or Progressive Malignant Glioma

• A Phase I/II Trial of BMS-247550 for Treatment of Patients with Recurrent High-grade Gliomas

• A Phse I, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Inravenous SDX-102 for the Treatment of Patients with MTAP-Deficient High Grade Malignant Gliomas

• A Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter

Class E: (Histology other than High Grade Astrocytoma)

• A Phase II Study of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Patients with Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)

Class F: (Non "Therapeutic" Protocols)

• A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas

• Pilot Study of Thrombophilic States in Patients with High-Grade Gliomas

• CD4 Count and Risk of Infection in Patients with Brain Tumors

• Identification of Hypermethylated Serum Tumor DNA in High Grade Glioma Patients and Correlation with Magnetic Resonance Imaging Findings

For information regarding the protocols available at this center, please contact:

Ruth Ann Beasse, RN
Case Manager, Research Nurse
Henry Ford Health System
JFCC Clinical Trials Office
2799 W. Grand Blvd., CFP-5 South
Detroit, MI 48202
Telephone: 313-916-3731
rbeasse1@hfhs.org